A recent study published in BioFactors suggests that lesser-known cannabinoids found in cannabis, including CBG, CBC, CBN, and CBDV, might offer promising anticancer effects against multiple myeloma (MM), a type of blood cancer. The research, conducted by a team from the University of Camerino in Italy and Vancouver-based Entourage Biosciences, explored the potential of these minor cannabinoids to combat MM in both cell and animal models.
The study revealed that CBG, CBC, CBN, and CBDV exhibited cytotoxic effects on MM cell lines, with CBN demonstrating the most significant impact in an in vivo mouse model. The researchers observed that these cannabinoids not only inhibited the growth of MM cells but also induced necrotic cell death and reduced cell invasion and bone resorption, particularly with CBG and CBN.
The study highlights the need for further investigation into these cannabinoids’ mechanisms and their efficacy in human trials. While cannabinoids like THC and CBD are well-studied for their therapeutic uses, this research brings attention to the potential of lesser-known compounds in cancer treatment.
The findings align with previous research suggesting that cannabinoids could play a role in cancer treatment beyond symptom management. As interest in the therapeutic benefits of cannabinoids grows, studies like these underscore the potential for new, targeted treatments for cancer patients, especially those resistant to conventional therapies.
Researchers emphasize the importance of continued exploration into the effects of these cannabinoids to fully understand their therapeutic potential and how they might complement existing cancer treatments.
Stay informed with daily updates on cannabis business news by subscribing to our newsletter.
